Pregnancy Outcomes in Multiple Sclerosis Management
Summary
Pregnancy in women with multiple sclerosis (MS) represents a critical period in which immune modulation, disease activity and therapeutic choices must be carefully balanced. During gestation, a natural shift towards anti-inflammatory immunity often leads to a reduction in clinical relapses, particularly in the third trimester. However, this remission is commonly followed by a rebound of disease activity in the first months after delivery. The safety of in utero exposure to disease-modifying therapies (DMTs) such as interferon-beta, glatiramer acetate and natalizumab has been progressively elucidated through large registries, demonstrating no substantial increase in adverse foetal or neonatal outcomes when treatment is appropriately timed. Ongoing research has clarified the risks associated with early withdrawal of high-efficacy agents and underscored the importance of individualised counselling on breastfeeding, postpartum relapse prophylaxis and reintroduction of therapy. Practical management now emphasises preconception planning, multidisciplinary collaboration and evidence-based guidelines to optimise both maternal neurological status and obstetric outcomes on a global scale.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Pregnancy Outcomes in Multiple Sclerosis Management publication trend
The graph below shows the total number of articles in pregnancy outcomes in multiple sclerosis management across all publications each year (not limited to Nature Index journals).
Technical terms
Relapse: A new or worsening neurological episode reflecting active inflammation in MS.
Expanded Disability Status Scale (EDSS): A numerical scale (0–10) assessing MS-related disability based on clinical examination.
Disease-modifying therapy (DMT): A treatment designed to alter the course of MS by reducing relapse frequency or delaying progression.
Spontaneous abortion: The unplanned loss of a pregnancy before 22 weeks of gestation.
References
- Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurology (2016).
- Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology (2012).
- Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy. JAMA Network Open (2022).
- Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. Journal of Neurology (2020).
- Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. Journal of Drug Assessment (2020).
- Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis. PLOS ONE (2010).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.